ClinicalTrials.gg
RecruitingNCT07306624Updated Jul 16, 2026

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

A Phase 2 interventional study of Nelmastobart and Docetaxel in Non Small Cell Lung Cancer, sponsored by STCube, Inc.. Recruiting at 5 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by STCube, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
80th of 188
62 · median 50
Started
2026
with 1 other
Phase 2
125 of 198
9 open now
Primary completion
2027-08
later than 14 of 19 live
Registered
197th of 198
by date

Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 80th largest by planned enrollment of the 188 interventional ones that give a count, is one of 2 that started in 2026, is one of 125 in phase 2, reaches primary completion later than 14 of the 19 other live ones, and was the 197th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy

Read the detailed description

This is a singble arm, open label, phase 2 study to evaluate safety and preliminary efficacy for Nelmastobart 800mg and docetaxel 75mg/m2 combination regimen for both AGA negative and positive NSCLC patients who have failed at least 1 line of platinum based chemotherapy.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • BTN1A1
  • nsclc
  • immune check point inhibitor
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed stage IIIb, IIIc, or IV recurrent NSCLC
  • BTN1A1 TPS score ≥50
  • Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
  • Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or at least 1platinum-based chemotherapy
  • (ECOG) performance status (PS) of 0- 1.
  • Adequate organ function as described in the protocol
  • Adequate cardiac function as described in the protocol
  • For female or male patients with : Agree to use throughout the study and at least 5 months after the last dose.
  • of at least 3 months
  • Has agreed to provide

Exclusion criteria

Exclusion Criteria:

  • Known to the active ingredients or of the study drug.
  • History of using Docetaxel for palliative therapy.
  • Prior treatment with Cytotoxic chemotherapy or oral targeted therapy within 14 days.
  • drugs within 5 half-lives.
  • Monoclonal antibodies or ADCs within 4 weeks.
  • Use or expected use of strong inhibitors (e.g., ketoconazole) within 14 days prior to the first dose.
  • Uncontrolled severe infection requiring IV treatment, or suspected infectious complications/fever.
  • Requirement for continuous high-dose (>10 mg/day prednisone equivalent) or within 7 days (excluding Docetaxel premedication; intermittent/replacement therapies allowed).
  • Pregnant or breastfeeding women.
  • History of disease requiring systemic treatment within the last 2 years
  • Known active symptomatic or radiologically unstable CNS lesions
  • History of stroke, unstable angina, MI, or Class III-IV symptoms within 6 months, or current Class II.
  • Systolic BP 160 mmHg or Diastolic BP 100 mmHg, or hypertensive encephalopathy.
  • History of ILD, organizing/drug-induced pneumonia, or active pneumonia on screening (mild asymptomatic fibrosis requires consultation).
  • Recipients of allogeneic stem cell or solid organ transplants.
  • Vaccination with live or attenuated within 30 days.
  • Maligancies other than NSCLC
  • Failure to recover from prior anti-cancer therapy side effects to Grade 1
  • Wide-field bone marrow radiation (>30%) within 4 weeks, or limited palliative radiation within 2 weeks.
  • Major surgery within 4 weeks or incomplete recovery from surgical side effects.
  • Evidence of active , , or infection (carriers with negative viral loads/RNA may be eligible).
  • Clinically unstable pleural or peritoneal effusion (stable cases after intervention are allowed).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Nelmastobart 800mg+Docetaxel 75mg/m2

    Nelmastobart 800mg+Docetaxel 75mg/m2 fixed

    Drug: Nelmastobart and Docetaxel

Interventions

  • DrugNelmastobart and Docetaxel

    Drug pages: Nelmastobart · Docetaxel

    Nelmastobart 800mg and Docetaxel 75mg/m2

06

What researchers measure

Primary outcomes

  1. Progression free survival by central reviewer

    Time from first dose until the date of objective disease progression or death assessed by central reviewer

    Time frame: up to 3 years

Secondary outcomes

  1. Overall survival

    Time from first dose of study drug until the date of death

    Time frame: up to 3 years

  2. Progression Free Survival assessed by Investigator

    Time from first dose until the date of objective disease progression or death

    Time frame: Up to 3 years

  3. Objective response rate, ORR

    Proportional of subjects with confirmed PR/CR, assessed by investigator and central reviewer

    Time frame: Up to 3 years

  4. Disease control rate, DCR

    Proportion of subjects with confirmed CR, PR, and SD assessed by investigator and central reviewer based on RECIST v1.1

    Time frame: Up to 3 years

  5. Duration of Response

    Time from the date of first objective response (CR or PR) after investigational drug administration to the first documented disease progression (PD) or death from any cause, with documentation of disease progression status and cause of death, assessed by investigator and central reviewer based on RECIST v1.1

    Time frame: Up to 3 years

  6. Progression free survival rate

    the proportion of patients without documented progression and alive 6 months after the first dose of study drug

    Time frame: 6 month

  7. Cmax

    Maximum plasma concentration

    Time frame: 3 weeks

  8. Area under concentration-time curve

    Area under the concentration-time curve during steady state

    Time frame: 15 weeks

  9. Adverse event

    Incidence and severity of AE determined according to National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] Version \[v\] 5.0

    Time frame: time from the date of the first dose of study drug until 30 days after last dose

Other outcomes

  1. Quality of life measured by EQ-5D-5L

    Change from Baseline in Patient Reported Outcome EQ-5D-5L at Treatment Cycle 2 and beyond

    Time frame: until the end of treatment (Up to 3 years)

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 19 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Dec 29, 2025
StartActual
Jan 10, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07306624
Lead sponsor
STCube, Inc.
Responsible party
Sponsor
First posted
Dec 29, 2025
Start date
Jan 10, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Heeyeon Jung
Contact
junghy@stcube.com
82-2-551-3370

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nelmastobart · Docetaxel

Start the discussion